ATRTInnovRT-2NCT04987476
Rhabdoid Tumors Cellular Architecture by Single-cell Analyses (InnovRT-2)
An observational study of ATRT, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
The aim is to describe at the cellular level the heterogeneity of rhabdoid tumors, and identify how this diversity influences resistance to treatment. Read more about this study
- Who is it for?
- Ages Up to 17 years
- Conditions the study is for
- ATRT
- What is being tested?
- analyzes in singles cells
- How many people
- 15 participants
- Where
- 1 siteFrance
- Study dates
- 31 Mar 2022to 21 Feb 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 17 years
- All sexes
- No healthy volunteers
- Child
Study population: Children having or likely having a rhabdoid tumor according to clinical and radiological features
Who may be able to join
- Aged 0-17 years old
- having a rhabdoid tumor according to clinical and radiological features Or likely having a rhabdoid tumor according to clinical and radiological features
- surgical resection in standard care
- sufficient material for both diagnosis and experimental procedures
- parents' agreement
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Hétérogénéité Des Tumeurs Rhabdoides : Approches en " Cellules Uniques " Pour Identifier Des Cibles thérapeutiques
The aim is to describe at the cellular level the heterogeneity of rhabdoid tumors, and identify how this diversity influences resistance to treatment.
Read the detailed description
Rhabdoid tumors are aggressive cancers of infancy. Although frequently chemosensitive at the very beginning, they very often show resistance, suggesting some intra-tumor diversity or plasticity. Moreover, morphological analysis of rhadoid tumors often reveal some variety in tumor cell shapes and immunohistochemical profiling. Altogether, this suggests some intra-tumor heterogeneity, that has been scarcely studied so far.
This project aims to describe the intra-tumor heterogeneity by single-cell sequencing approaches.
After surgical resection, fresh tumor samples will be dissected and analysed using the 10X Chromium technology. Briefly, cells will be grouped in clusters according to their gene expression signalling, and each cluster will be defined in comparison with all other ones. Differential analyses will allow identifying the main characteristic of each cell sub-population. Potential filiations between clusters will be analysed using classical algorithms. The study will be performed on 10 to 15 tumor samples.
- Conditions
- ATRT
- Being tested
- analyzes in singles cells
- Keywords
- ATRT, SMARCB1, single-cell RNAseq
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
analyzes in singles cellsBiological
genome expression analyzes in single cells
| Study group | Role | What they receive |
|---|---|---|
| ATRT | Children affected by an ATRT at time of surgical resection Receives: Biological: analyzes in singles cells |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intra-tumor heterogeneity
Identification of cell clusters - mean expression (RPKM unit) of gene set signtaures in each bioinformatically defined cluster
Measured: Inclusion
Secondary outcomes (3)
Cell clusters recurrent from one sample to the other
Fraction/percentage of cell clusters defined by primary outcome that are specific to each tumor and those that are shared by several or all samples
Measured: Inclusion
Naming of potential targetable gene
Mean expression (RPKM unit) of targetable genes (defined by the existence of adequate pharmacological inhibitor) in each tumor sample and clusters
Measured: Inclusion
Identification of cytotoxic cells
Conducting therapeutic biological functional tests
Measured: Inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2021
- Study start31 Mar 2022
- Primary completion21 Feb 2025
- Study completion21 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ATRTStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Collaborators
- Institut Curie, URC-CIC Paris Descartes Necker Cochin
- Responsible party
- Sponsor
- Investigators
- Kevin Beccaria, MD, PhD, Pr, Study director, APHP Assistance Publique des Hôpitaux de Paris
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04987476
- Sponsor's protocol ID
- APHP200122
- Other IDs
- 2021-A00795-36
- Acronym
- InnovRT-2
- Status last verified
- Oct 2025
- First submitted
- 31 Jul 2021
- Last updated
- 20 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hétérogénéité Des Tumeurs Rhabdoides : Approches en " Cellules Uniques " Pour Identifier Des Cibles thérapeutiques
- ClinicalTrials.gov ID
- NCT04987476
- Acronym / sponsor ID
- InnovRT-2 / APHP200122
- Conditions
- ATRT
- Keywords
- ATRT, SMARCB1, single-cell RNAseq
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Collaborators
- Institut Curie, URC-CIC Paris Descartes Necker Cochin
- Study start
- 31 Mar 2022 (actual)
- Primary completion
- 21 Feb 2025 (actual)
- Study completion
- 21 Feb 2025 (actual)
- First posted
- 3 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim is to describe at the cellular level the heterogeneity of rhabdoid tumors, and identify how this diversity influences resistance to treatment.
Detailed description
Rhabdoid tumors are aggressive cancers of infancy. Although frequently chemosensitive at the very beginning, they very often show resistance, suggesting some intra-tumor diversity or plasticity. Moreover, morphological analysis of rhadoid tumors often reveal some variety in tumor cell shapes and immunohistochemical profiling. Altogether, this suggests some intra-tumor heterogeneity, that has been scarcely studied so far.
This project aims to describe the intra-tumor heterogeneity by single-cell sequencing approaches.
After surgical resection, fresh tumor samples will be dissected and analysed using the 10X Chromium technology. Briefly, cells will be grouped in clusters according to their gene expression signalling, and each cluster will be defined in comparison with all other ones. Differential analyses will allow identifying the main characteristic of each cell sub-population. Potential filiations between clusters will be analysed using classical algorithms. The study will be performed on 10 to 15 tumor samples.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| ATRT | – | Biological: analyzes in singles cellsChildren affected by an ATRT at time of surgical resection |
Who may qualify
- Ages
- Up to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Children having or likely having a rhabdoid tumor according to clinical and radiological features
Key inclusion criteria (5 listed)
- Aged 0-17 years old
- having a rhabdoid tumor according to clinical and radiological features Or likely having a rhabdoid tumor according to clinical and radiological features
- surgical resection in standard care
- sufficient material for both diagnosis and experimental procedures
- parents' agreement
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| analyzes in singles cellsgenome expression analyzes in single cells | Biological | ATRT |
Primary outcome
Intra-tumor heterogeneity
Time frame: Inclusion
Identification of cell clusters - mean expression (RPKM unit) of gene set signtaures in each bioinformatically defined cluster
3 secondary outcomes
Cell clusters recurrent from one sample to the other
Time frame: Inclusion
Naming of potential targetable gene
Time frame: Inclusion
Identification of cytotoxic cells
Time frame: Inclusion
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for ATRT
RecruitingPhase 2
Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)
Recurrent Atypical Teratoid/Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS
RecruitingPhase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Medulloblastoma Recurrent, Ependymoma Recurrent
RecruitingPhase 1
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Medulloblastoma, Central Nervous System Embryonal Tumor
Active, not recruitingPhase 1
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
Pediatric Solid Tumor, Pediatric Lymphoma
RecruitingPhase 1
NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors
Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma, High Grade Gliomas
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kevin Beccaria, MD, PhD, Pr study director
APHP Assistance Publique des Hôpitaux de Paris
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of ATRT, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intra-tumor heterogeneity (time frame: Inclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2025.